In this session, A/Prof Tran explains the principles of trial-based economic evaluation, the limitations of incremental cost-effectiveness ratios (ICERs), and the challenges of representing and interpreting uncertainty. He then introduces the net benefit framework as an alternative approach for analysing uncertainty and supporting healthcare decision-making.
Using a real-world case study in arthroplasty prophylaxis, the webinar demonstrates the economic evaluation of adding vancomycin to cefazolin for the prevention of surgical site infections. The findings suggest that omitting vancomycin from prophylaxis may deliver significant cost savings to the healthcare system while maintaining comparable clinical outcomes and health-related quality of life.
The session also explores the limitations of trial-based economic evaluations in capturing the broader costs associated with antimicrobial resistance and discusses how modelling approaches can help address these challenges.
Whether you’re a clinical researcher, health economist, policymaker, or healthcare professional, this webinar provides valuable insights into contemporary methods for evaluating the cost-effectiveness of healthcare interventions.
Resource Documents
